RespireRx Pharmaceuticals Inc.

RespireRx Pharmaceuticals Inc. is a biopharmaceutical company developing innovative and revolutionary treatments to combat disorders caused by disruption of neuronal signaling.

In the News

5/24/23 – ResolutionRx Ltd, a Subsidiary of RespireRx Pharmaceuticals Inc., Enters into Letter of Intent with Cantheon Capital for the Financing of Anticipated Research and Development Costs

May 24, 2023

4/5/23 – RespireRx Pharmaceuticals Inc. Establishes Research Collaboration with University College London to Study the Use of AMPAkines for the Treatment of GRIA Disorders

April 5, 2023

4/3/23 – RespireRx Pharmaceuticals Inc. Discloses Novel Structural Analogs of its GABA Receptor Potentiator, KRM-II-81 with Antiseizure Efficacy and Antitremor Effects without Sedation

April 3, 2023

WATCH: RespireRx CSO Arnold Lippa Discusses Collaboration with University College London to Study Treatment Options for GRIA Disorders

WATCH: RespireRx CFO Jeff Margolis Shares Updates Following ResolutionRx Services Agreement with Australian CRO iNGENu